Echocardiographic Assessment of Intrapulmonary Vasodilatation: Agitated Saline Versus Polygeline

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2007 by Medical University of Vienna.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Medical University of Vienna
ClinicalTrials.gov Identifier:
NCT00343122
First received: June 20, 2006
Last updated: September 14, 2007
Last verified: September 2007
  Purpose

The purpose of the study is to evaluate agitated saline versus polygeline for detection of intrapulmonary vasodilatation in patients with cirrhosis.


Condition Intervention Phase
Liver
Cirrhosis
Procedure: echocardiography for intrapulmonary vasodilatation
Phase 4

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Official Title: Evaluation of Two Methods for the Echocardiographic Assessment of Intrapulmonary Vasodilatation in Patients With Liver Cirrhosis: Agitated Saline Versus Polygelatine

Resource links provided by NLM:


Further study details as provided by Medical University of Vienna:

Estimated Enrollment: 100
Study Start Date: June 2006
Detailed Description:

Intrapulmonary vasodilatation is a frequent finding in patients with cirrhosis. Its diagnosis is established via contrast enhanced echocardiography. One used method is the contrast agent agitated saline and another frequently used method is the contrast agent polygeline. The purpose of this study is to compare these two echocardiographic contrast agents with respect to their ability to detect intrapulmonary vasodilatation.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age > 18 years
  • presence of liver cirrhosis
  • evaluation for liver transplantation or transjugular intrahepatic portosystemic shunt

Exclusion Criteria:

  • inadequate echocardiographic image quality
  • allergies to echocardiographic contrast agents
  • pulmonary valve stenosis
  • pulmonary embolism
  • relevant tricuspid regurgitation
  • cardiomyopathy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00343122

Contacts
Contact: Valentin Fuhrmann, MD 0043-1-40400 ext 4766 valentin.fuhrmann@meduniwien.ac.at
Contact: Peter Schenk, MD 0043-1-40400 ext 4766

Locations
Austria
Intensive Care Unit 13H1, Dep. of Internal Medicine IV, Medical University of Vienna Recruiting
Vienna, Austria, A-1090
Contact: Valentin Fuhrmann, MD    0043-1-40400 ext 4766    valentin.fuhrmann@meduniwien.ac.at   
Principal Investigator: Peter Schenk, MD         
Sub-Investigator: Valentin Fuhrmann, MD         
Sponsors and Collaborators
Medical University of Vienna
Investigators
Principal Investigator: Peter Schenk, MD Intensive Care Unit 13h1, Dep. of Internal Medicine IV, Medical University of Vienna
  More Information

Publications:
Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB; ERS Task Force Pulmonary-Hepatic Vascular Disorders (PHD) Scientific Committee. Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J. 24(5):861-80,2004.

ClinicalTrials.gov Identifier: NCT00343122     History of Changes
Other Study ID Numbers: EK 4462005
Study First Received: June 20, 2006
Last Updated: September 14, 2007
Health Authority: Austria: Federal Ministry for Health and Women

Keywords provided by Medical University of Vienna:
liver
cirrhosis
hepatopulmonary syndrome

Additional relevant MeSH terms:
Liver Cirrhosis
Fibrosis
Liver Diseases
Digestive System Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on August 28, 2014